Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Multiple Myeloma 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Lung Neoplasms 2Hematologic Neoplasms 2Gastrointestinal Stromal Tumors 2Advanced Malignancies 2Solid Tumor 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Neoplasms 1Melanoma 1Liposarcoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Diseases 1Carcinoma, Squamous Cell 1Carcinoma, Large Cell 1

Interventions

Injections 12pembrolizumab 11Nivolumab 9Paclitaxel 8senaparib 7Docetaxel 7Cisplatin 6Capecitabine 6Gemcitabine 5toripalimab 4tislelizumab 4atezolizumab 4Ipilimumab 4Carboplatin 4Bevacizumab 4sintilimab 3Rifampin 3Oxaliplatin 3Itraconazole 3130-nm albumin-bound paclitaxel 3zimberelimab 2pertuzumab 2osimertinib 2ontuxizumab 2navoximod 2magrolimab 2fluzoparib 2famitinib 2durvalumab 2camrelizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Solid Tumor × tanespimycin × Clear all
NCT00820768 2018-04-11

A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Celgene

Phase 1 Withdrawn
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡